AstraZeneca PLC on Sunday said its rescue medication candidate PTO27 showed positive results in its Mandala Phase III trial.
The inhaled corticosteroid ‘demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma,’ AstraZeneca explained. Corticosteroids are a class of anti-inflammatory hormones naturally produced in the adrenal gland.
A combination of 180 micrograms of albuterol and 160 micrograms of budesonide ‘reduced the risk of a severe exacerbation by 27% in adults and adolescents,’ the Cambridge, England-based pharmaceutical company said.
PTO27 is a combination of asthma-medications albuterol and budesonide. It is being developed by AstraZeneca and late-stage London-based drug developer Avillion LLP.
Albuterol has been used to treat asthma since the late 1960s, and budesonide since 1981.
GlaxoSmithKline PLC, which changed its name to GSK PLC on Monday, produces Albuterol under its brand name Ventolin, which is distributed by Ohio-based Prasco LLC. AstraZeneca is one of several companies that produces budesonide.
Shares in AstraZeneca were 0.4% higher at 10,326.00 pence each in London on Monday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.